Monday, June 12, 2023
- Eight winners of the Artificial Kidney Prize Phase 2 were announced at the KidneyX Summit.
- The competition recognized innovative bioartificial kidney development approaches, awarding $1.6 million to two Track 1 participants and $1 million to six Track 2 participants.
- The prize aims to revolutionize kidney care and develop solutions in xenotransplantation and regenerative medicine, potentially reducing the burdens of kidney disease.
- 850 million people globally suffer from kidney diseases, with treatment in the US alone costing over $100 billion annually. Each day, 13 people die waiting for a kidney transplant.
- The development of a fully functional bioartificial kidney is challenging due to the organ’s complexity, but KidneyX aims to advance this field, which has seen limited progress in over 60 years.
- HHS reaffirmed its commitment to advancing kidney care through the KidneyX partnership and congratulated the Artificial Kidney Prize Phase 2 winners.
Unedited Press Release Text:
Washington, DC (June 12, 2023) — Today, the Kidney Innovation Accelerator (KidneyX), a public private partnership between the US Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) announced the eight winners of the Artificial Kidney Prize Phase 2 at the KidneyX Summit in Washington, DC. The competition recognized participants’ innovative approaches to developing a bioartificial kidney and was divided into two tracks with two Track 1 participants each receiving $1,600,000, and six Track 2 participants each receiving $1,000,000.
“Kidney diseases are common, serious, and deadly. People with kidney diseases have demanded innovative treatment technologies and management strategies to replace dialysis, which has changed slowly and incrementally over 50 years. The nephrology scientific community has responded with a pipeline of discoveries that promise to revolutionize kidney care. The Artificial Kidney Prize Phase 2 winners highlight paradigm-shifting solutions in xenotranplantation and regenerative medicine that are being developed to reduce the burdens of kidney disease,” said John R. Sedor, MD, FASN, KidneyX Steering Committee Chair.
850 million people worldwide have kidney diseases including 37 million Americans. In the United States alone, treatment costs total more than $100 billion a year. Each day, 13 people die while waiting for a kidney transplant, while those on dialysis face a 50 percent mortality rate during the first five years of treatment. Black, rural, and socioeconomically disadvantaged Americans are disproportionately affected with increased incidence, fewer organs available for transplant, and poorer outcomes overall.
Development of a fully functional bioartificial kidney has proven difficult in the past because of the overall complexity of the organ, which is made up of a multitude of cell types and performs several important functions.
Innovation is urgently needed. Through this prize competition, KidneyX is seeking to advance a field that has seen little progress in more than 60 years. The best treatment is a kidney transplant, but the supply of organs only addresses a small fraction of the need. Phase 2 of the Artificial Kidney Prize competition invited submissions focused on either developing prototype bioartificial kidneys or a new tool or component that can help enable the development of bioartificial kidneys. Innovators in the fields of regenerative medicine, cellular engineering, tissue engineering, systems biology, and synthetic biology were encouraged to apply.
“HHS is excited and remains committed to advancing kidney care through the KidneyX partnership. I congratulate the winners of the Artificial Kidney Prize Phase 2 competition. This prize competition is leading us into the next steps for advancements and solutions in the artificial kidney developments,” said Assistant Secretary for Health Admiral Rachel L. Levine, MD.
All prize recipients are listed below and their bios can be found here .
Anthony Atala, MD, Track 2
3D vascularized biomimetic renal construct platform for accelerated vascular integration
William Chang, MD, PhD, Track 2
Engineering bioartificial kidneys: Combining kidney organoids and peritoneal dialysis
David K.C. Cooper, MD, PhD, FRCS, Track 1
Alemtuzumab induction therapy in monkeys with life-supporting pig kidney transplants
Nils Olof Lindström, PhD, Track 2
Draining artificial kidneys by connecting synchronized nephrons to synthetic organizers
Harald C. Ott, MD, Track 2
Manufacturing and system dynamics tools enabling autonomous blood purification implants
Shuvo Roy, PhD, Track 2
Immunoprotective bioreactor for kidney cell encapsulation
Ben Shepherd, PhD, Track 2
Bioengineered therapies for patients with kidney failure
Matt Tector, PhD, Track 1
Renal Xenograft Phase 2: Solving the donor kidney shortage
About U.S. Department of Health and Human Services
The U.S. Department of Health and Human Services (HHS) enhances and protects the health and well-being of all Americans. HHS fulfills that mission by providing for effective health and human services and fostering advances in medicine, public health, and social services. For more information visit https://www.kidneyx.org/ or email firstname.lastname@example.org.
About American Society of Nephrology
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has nearly 20,000 members representing 132 countries. For more information, please visit asn-online.org and follow us on Facebook , Twitter , LinkedIn , and Instagram.
Join the Newsletter
What’s better than free news straight from the source?